This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.
Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall
by Zacks Equity Research
Baxter (BAX) recalls Life2000 ventilators due to damaged battery charger dongles, posing a risk of device failure
Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital
by Zacks Equity Research
Smith & Nephew (SNN) eyes future growth as Cevian Capital purchases a 5% stake in the company.
Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
by Zacks Equity Research
BD's (BDX) robust product portfolio raises optimism about the stock.
Masimo (MASI) Fights Politan in a Bid to Retain CEO on Board
by Zacks Equity Research
Will Masimo (MASI) lose its CEO in its fight against activist investor Politan Capital Management? The company's management and employees want Joe Kiani to continue as the CEO.
DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs
by Zacks Equity Research
Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.
Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial
by Zacks Equity Research
Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures.
Cardinal Health (CAH) Recalls Kits Containing Shenli's Syringes
by Zacks Equity Research
Cardinal Health (CAH) recalls its procedure kits that contain plastic syringes manufactured by a Chinese manufacturer, Jiangsu Shenli.
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
by Zacks Equity Research
Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.
KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan
by Zacks Equity Research
KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan.
Merit Medical (MMSI) Inks Deal to Boost Endoscopy Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) latest asset acquisition is likely to expand its endoscopy portfolio with a minimally-invasive solution for GERD patients, thereby improving patient outcomes.
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
by Zacks Equity Research
IceCure Medical's (ICCM) XSense Cryoablation System receives FDA approval, marking a pivotal step in minimally-invasive tumor treatment across multiple medical fields
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Avantor (AVTR) Launches Solutions for Gene Therapy Harvest
by Zacks Equity Research
Avantor's (AVTR) solutions are intended to provide gene therapy manufacturers with sustainable and efficient alternatives to traditional methods, thus improving viral particle harvest and quality
Masimo's (MASI) WI Sport Wearable Gets a New Powerful Feature
by Zacks Equity Research
Masimo (MASI) announces Sleep Halo, a new feature for its Masimo W1 Sport advanced health tracking wearable.
GE Healthcare (GEHC) Enters Partnership to Boost MRI Technology
by Zacks Equity Research
GE Healthcare's (GEHC) alliance is likely to establish an Innovative MRI Research and Development center to advance MRI innovation and patient care
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
by Zacks Equity Research
Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes
PacBio (PACB) and Form Bio to Boost AAV Industry Development
by Zacks Equity Research
PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.
Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.
Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down
by Zacks Equity Research
An increasingly challenging pharmacy industry and consumer environment hurt Walgreens Boots' (WBA) bottom line in the third quarter of fiscal 2024.
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care
by Zacks Equity Research
Masimo (MASI) collaborates with Cleveland Clinic to boost patient care by combining its Hospital Automation platform with the latter's central patient monitoring platforms.